NASDAQ:NDRA

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

Retrieved on: 
Tuesday, May 7, 2024
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, International, NDRA, PIN

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets.

Key Points: 
  • ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets.
  • Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.
  • Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator.
  • A telephone replay will be available until May 21, 2024 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 8128350.

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

Retrieved on: 
Thursday, May 2, 2024
Science, Radiology, Research, Medical Supplies, Surgery, Health, Medical Devices, Health Technology, IP, NDRA, European Patent Convention, Patent, RF, Intellectual property, Thermoacoustic imaging, Temperature, Cryotherapy

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China.
  • ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology.
  • "With the issuance of these five patents, we've reached a significant milestone of 80 global patents," said Francois Michelon, ENDRA's Chairman and CEO.
  • "Our extensive IP portfolio safeguards and sets apart ENDRA’s thermoacoustic technology in areas of high unmet clinical need.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Retrieved on: 
Thursday, March 21, 2024
Managed Care, Hospitals, Health, Medical Devices, International, PIN, NDRA

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets.

Key Points: 
  • ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets.
  • Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.
  • Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator.
  • A telephone replay will be available until April 4, 2024 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 8041087.

ENDRA Life Sciences Installs First TAEUS System in the UK

Retrieved on: 
Tuesday, February 27, 2024
Health, Medical Devices, Surgery, Health Technology, Other Health, Radiology, Biotechnology, Hospital, National Health Service, NDRA, NHS, KCH, King, Trial of the century, MRI, Partnership, Nursing

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health Service (NHS).

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health Service (NHS).
  • KCH will use ENDRA's TAEUS liver system in a clinical study to compare its liver fat assessment accuracy with MRI, the acknowledged research standard.
  • This study is expected to include approximately 75 subjects, and is intended to provide essential data to evaluate the TAEUS technology's performance.
  • ENDRA's versatile TAEUS system could potentially be suited for such outreach initiatives in the future."

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System

Retrieved on: 
Wednesday, February 21, 2024
FDA, Health, Diabetes, Surgery, Health Insurance, Pharmaceutical, Therapy, CE, American Diabetes Association, NAFLD, Endocrinology, T2D, Research, Medicine, Person, CMS, Non-alcoholic fatty liver disease, Liver disease, NDRA, Prediabetes, Obesity, Cardiovascular disease, Food, ALT, De novo, Global health, Weill Cornell Medicine, Risk, Hepatology, Cirrhosis, European, Prevalence, Ultrasound, World Health Organization, Medicare, Type 2 diabetes, Metabolic syndrome, Patient, Fibrosis, Primary care, Fatty liver disease, NASH, Diagnosis, Knowledge Organization (journal), WHO, International Classification of Diseases, Dietary supplement

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.

Key Points: 
  • The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), is a global coding system used to indicate a diagnosis for reimbursement purposes.
  • These codes are issued by the World Health Organization (WHO) and are used to show payers why a particular service was medically necessary.
  • The inclusion of NAFLD under the ICD-10 K76.0 code facilitates standardized billing for its diagnosis.
  • "This positive development is testament to the growing awareness of liver health and the intensifying need for effective diagnostic solutions.

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, Health, Surgery, Medical Devices, Temperature, NDRA, Cryotherapy, Integration, European Patent Convention, Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.
  • ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology.
  • These patents protect novel innovations integral to the TAEUS system, ensuring maximum radiofrequency energy absorption, minimized signal noise and precise temperature monitoring during surgical procedures and thermal ablation.
  • "We remain committed to fortifying our intellectual property to safeguard our technology in key global markets, deploying a robust portfolio that now encompasses 74 granted patents."

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Retrieved on: 
Wednesday, November 29, 2023
Health, Medical Devices, Surgery, Health Technology, Other Health, Radiology, Biotechnology, U.S. Patent No. 1, Patent, NDRA, Pharmaceutical industry

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No.
  • 11730374, and is the second of two structural embodiments that ENDRA is patenting to further protect its core technology.
  • This 39th U.S. patent bolsters our thermoacoustic technology in areas of high unmet clinical need,” stated ENDRA’s Chairman and Chief Executive Officer Francois Michelon.
  • “With a total of 71 patents granted worldwide, ENDRA possesses robust IP protection for its novel TAEUS’ technology in key global markets.”

ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference

Retrieved on: 
Monday, November 27, 2023
Research, General Health, Radiology, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Surgery, Biotechnology, Other Science, Health, NDRA, Conference, Cryptocurrency, Auction

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will be participating in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference being held Thursday, December 7, 2023 at the New York Athletic Club in New York City.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will be participating in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference being held Thursday, December 7, 2023 at the New York Athletic Club in New York City.
  • Management will be holding one-on-one meetings with investors.
  • To schedule a one-on-one meeting with ENDRA, you may submit your request online via the link provided upon registration.
  • To register for the conference, please click here .

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Radiology, Health, Clinical Trials, Medical Devices, Proton, Sale, Magnetic resonance imaging, Hepatology, NAFLD, NDRA, Research, De novo, Food, Endocrinology, International, Magnetic resonance, PIN, Agency, FDA, Non-alcoholic fatty liver disease, Marketing, Liver, De novo synthesis, ATM, NPV, Fatty liver disease, Medical imaging, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • Highlights from the third quarter of 2023 and recent weeks include:
    Shared positive TAEUS clinical data at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver.
  • TAEUS estimates of liver fat fraction were strongly correlated to MRI-PDFF scores with a Pearson correlation coefficient of r=0.87.
  • During the third quarter of 2023 and recent weeks, ENDRA was issued six additional patents, including two in the U.S., two in Europe and two in China.